

# Helen L Lowe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1739452/publications.pdf>

Version: 2024-02-01

11  
papers

3,149  
citations

1937685

4  
h-index

1720034

7  
g-index

12  
all docs

12  
docs citations

12  
times ranked

6910  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2109-2121.	27.0	1,786
2	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. <i>Nature</i> , 2017, 545, 446-451.	27.8	1,287
3	Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 3352-3363.	1.6	59
4	AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL. <i>Blood</i> , 2019, 134, 226-226.	1.4	6
5	EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS6091-TPS6091.	1.6	4
6	VERONa Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. <i>JMIR Research Protocols</i> , 2019, 8, e13696.	1.0	4
7	Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion. <i>Blood</i> , 2019, 134, 776-776.	1.4	3
8	Antibody Directed Enzyme Prodrug Therapy (ADEPT). , 2009, , 336-349.		0
9	Feasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a biomarker in advanced endometrial cancer (aEC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5600-5600.	1.6	0
10	Abstract CT105: AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL. , 2019, , .		0
11	Phase 0 study of vandetanib-eluting radiopaque embolics as a pre-operative embolization treatment in patients with resectable liver malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.5	0